Received Jun 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | P2443 | — |
Early dose administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 75-year-old female patient who received HAB (Twinrix) (batch number P2443, expiry date 18-SEP-2027) for prophylaxis. Previously administered products included Twinrix (received 1st dose on an unknown date). Concomitant products included Hepatitis a vaccine inact, Hepatitis b vaccine rHBsAg (yeast) (Twinrix). On 06-JUN-2025, the patient received the 3rd dose of Twinrix. On 06-JUN-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too short (Verbatim: Early dose administration). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 09-JUN-2025 The pharmacist reported that a patient had administration of an early schedule dose of Twinrix to a female patient on 6th June 2025, which led to drug dose administration interval too short. According to the health care provider, the second dose was administered on 4th April 2025, and the third dose was scheduled for September 2025. The vaccine administration facility was the same as primary reporter.
TWINRIX